Dr. Peter Stirling (Stirling Lab) has received a one-year research grant through Brain Cancer Canada for his groundbreaking glioblastoma (GBM) research.
Dr. Stirling’s project, titled “Developing new dual function therapies that kill tumour cells and activate immune responses in glioblastomas,” targets the aggressive and notoriously treatment-resistant GBM tumours. These tumours often suppress local immune responses, making them difficult to treat with conventional chemotherapy alone. The research focuses on a novel chemotherapeutic approach that not only targets tumour cells but also activates the local immune system, potentially overcoming the immune resistance often seen in glioblastomas.
